MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.

LIMITED REVIEW REPORT AND INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS FOR THE SIX MONTHS PERIOD ENDED 30 JUNE 2026

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E.

Interim condensed separate financial statements
For the six months period ended 30 June 2026

Contents	**Page**

Limited review report
On the interim condensed separate financial statements

To the Board of Directors of Macro Group pharmaceutical Company (Macro Capital) S.A.E.

Introduction

We have conducted a limited review for the accompanying interim condensed separate statement of financial position of *Macro Group pharmaceutical Company(Macro Capital) S.A.E.* (the "Company") as of 30 June 2026 and the related interim condensed separate statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended. Management is responsible for the preparation and fair presentation of these interim condensed separate financial statements in accordance with the Egyptian Accounting Standard 30 “Interim financial reporting”, and our responsibility is limited to expressing a conclusion on these interim condensed separate financial statements based on our limited review.

Scope of the limited review

We have conducted our limited review in accordance with the Egyptian Standard on Review Engagements No. 2410 “Review of Interim Financial Statements Performed by the Independent Auditor of the Entity”. A limited review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed separate financial statements.

Conclusion

In light of our limited review, nothing has come to our attention that causes us to believe that the accompanying interim condensed separate financial statements are not prepared, in all material respects, in accordance with Egyptian Accounting Standard 30 “Interim financial reporting”.

PricewaterhouseCoopers Ezzeldeen, Diab & Co.

Mohamed ElSawaf
R.A.A. 39521
F.R.A. 419
12 August 2026
Cairo

PricewaterhouseCoopers Ezzeldeen, Diab & Co., Public Accountants
One Ninety-Building A2-Fifth Settlement, New Cairo 11835,
PO Box 170 New Cairo, Cairo, Egypt
Tel: +20 2 27597700, Fax: +02 2 27597711

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E

Interim condensed separate statement of financial position - As of 30 June 2026

(All amounts in Egyptian Pounds)

	Note	30 June 2026	31 December 2025
Non-current assets			
Property, plant and equipment	5	82,772,065	82,069,637
Right of use assets	6	42,168,504	40,040,659
Intangible assets	7	1,009,044	1,207,248
Investments in subsidiaries		34,153,891	34,153,891
Total non-current assets		**160,103,504**	**157,471,435**
Current assets			
Inventories	8	169,698,730	108,664,501
Trade and notes receivables	9	383,629,584	270,433,019
Prepayments and other debit balances		86,829,093	80,053,254
Due from related parties	10	1,157,042	485,325
Cash and cash equivalents	11	476,262,163	172,182,530
Total current assets		**1,117,576,612**	**631,818,629**
Total assets		**1,277,680,116**	**789,290,064**
Equity			
Capital	12	684,247,747	114,041,291
Legal reserve		37,803,781	37,803,781
Retained earnings		99,466,415	40,384,732
Total equity		**821,517,943**	**192,229,804**
Non-current liabilities			
Deferred tax liabilities		939,346	939,346
Lease liabilities		36,947,206	32,571,854
Loans from related parties	13-1	-	86,029,546
Total non-current liabilities		**37,886,552**	**119,540,746**
Current liabilities			
Loans from related parties	13-2	-	141,085,897
Provisions	14	60,678,966	52,180,565
Employee incentive plan	15	14,261,595	-
Banks facilities	16	-	6,948,071
Trade and notes payables		100,266,754	107,550,064
Creditors and other credit balances	17	210,890,696	134,751,133
Lease liabilities		12,095,808	12,910,060
Due to related parties	10	20,081,802	22,093,724
Income tax liabilities		-	-
Total current liabilities		**418,275,621**	**477,519,514**
Total liabilities		**456,162,173**	**597,060,260**
Total equity and liabilities		**1,277,680,116**	**789,290,064**

- The accompanying notes on pages 7 to 20 form an integral part of these interim condensed separate financial statements.

These interim condensed separate financial statements were approved and authorized for issue by the Board of Directors and signed on their behalf on 12 August 2026 by:

Khaled K.

Mr. Khaled Kamel
Chief Executive Officer

Dr. Ahmed El Nayeb
Chairman

Limited review report attached.

12 August 2026

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E

Interim condensed separate statement of profit or loss
For the six months period 30 June 2026

(All amounts in Egyptian Pounds)

	Note	Six months ended 30 June 2026	Six months ended 30 June 2025	Three months ended 30 June 2026	Three months ended 30 June 2025
Sales	18	575,205,106	411,396,518	302,947,553	227,083,344
Cost of sales	19	(169,265,573)	(131,268,830)	(88,489,455)	(69,136,184)
Gross profit		**405,939,533**	**280,127,688**	**214,458,098**	**157,947,160**
Selling and marketing expenses	19	(192,488,094)	(130,959,489)	(102,600,653)	(73,502,594)
General and administrative expenses	19	(99,838,601)	(57,479,833)	(43,815,324)	(28,017,620)
Expected credit losses on financial assets (Net)		-	(5,040,326)	-	(1,520,129)
Other expenses -net		(7,304,077)	(3,917,942)	(4,437,246)	(4,489,458)
Operating profits		**106,308,761**	**82,730,098**	**63,604,875**	**50,417,359**
Finance cost	20	(18,844,108)	(19,388,199)	(7,931,100)	(9,039,110)
Finance income	20	24,455,517	7,941,182	12,591,025	5,447,687
Net finance income/(cost)	20	**5,611,409**	**(11,447,017)**	**4,659,925**	**(3,591,423)**
Net profits for the period before income tax		**111,920,170**	**71,283,081**	**68,264,800**	**46,825,936**
Income tax expense		**(26,108,487)**	-	**(16,070,384)**	-
Net profits for the period		**85,811,683**	**71,283,081**	**52,194,416**	**46,825,936**
Earnings per share from the net profits for the period:					
Basic Earnings per share	21	0.03	0.13	0.02	0.08
Diluted Earnings per share	21	0.03	0.13	0.02	0.08

- The accompanying notes on pages 7 to 20 form an integral part of these interim condensed separate financial statements.

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E

Interim condensed separate statement of comprehensive income
For the six months period 30 June 2026

(All amounts in Egyptian Pounds)

	Six months ended 30 June		Three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Net profits for the period	85,811,683	71,283,081	52,194,416	46,825,936
Other comprehensive income for the period, net of tax	-	-	-	-
Total comprehensive income for the period	**85,811,683**	**71,283,081**	**52,194,416**	**46,825,936**

- The accompanying notes on pages 7 to 20 form an integral part of these interim condensed separate financial statements.

MACRO GROUP PHARMACEUTICAL COMPANY (MACRO CAPITAL) S.A.E

Interim condensed separate statement of changes in equity
For the six months period 30 June 2026

(All amounts in Egyptian Pounds)

	Capital	Legal reserve	(Accumulated losses)/ Retained Earnings	Total equity
Balance at 1 January 2025	**114,041,291**	**32,232,799**	**(65,463,924)**	**80,810,166**
Total comprehensive losses for the period	-	-	71,283,081	**71,283,081**
Transferred to legal reserve	-	3,564,154	(3,564,154)	-
Balance at 30 June 2025	**114,041,291**	**35,796,953**	**2,255,003**	**152,093,247**
Balance at 1 January 2026	**114,041,291**	**37,803,781**	**40,384,732**	**192,229,804**
Share Capital increase	570,206,456	-	-	**570,206,456**
Total comprehensive income for the period	-	-	85,811,683	**85,811,683**
dividends	-	-	(26,730,000)	**(26,730,000)**
Balance at 30 June 2026	**684,247,747**	**37,803,781**	**99,466,415**	**821,517,943**

- The accompanying notes on pages 7 to 20 form an integral part of these interim condensed separate financial statements.

Interim condensed separate statement of cash flows
For the six months period 30 June 2026

(All amounts in Egyptian Pounds)

	Note	30 June 2026	30 June 2025
Cash flows from operating activities			
Net profits for the period before income tax		111,920,170	71,283,081
Adjustments for:			
Depreciation and amortization	19	12,313,165	8,237,356
Interest income	20	(24,455,517)	(3,743,857)
Interest expense	20	997,149	16,248,888
Lease interest Expense		5,274,291	3,139,311
Employee incentive plan		14,261,595	-
Inventory Impairment		-	5,988,173
Related party loans revaluation		-	(6,156,342)
Expected credit losses on financial assets — net		-	5,040,326
Inventory provision formed		10,172,912	5,000,000
Other income – net		(145,386)	(9,423)
Operating profits before changes in working capital		**130,338,379**	**105,027,513**
Changes in working capital			
Inventories		(61,034,229)	(10,269,061)
Trade and notes receivables		(113,196,565)	(21,412,481)
Prepayments and other debit balances		(6,775,839)	(12,195,236)
Due from related parties		(671,717)	(420,654)
Trade and notes payables		(7,283,310)	3,757,803
Creditors and other credit balances		23,308,896	(6,444,944)
Due to related parties		(2,011,922)	(2,141,030)
Provision utilized		(1,674,511)	(16,759,164)
Cash flows (used in) /generated from operating activities		**(39,000,818)**	**39,142,746**
Interest paid		(997,149)	(7,238,386)
Net cash flow (used in) /generated from operating activities		**(39,997,967)**	**31,904,360**
Cash flows from investing activities			
Payments for purchase of property, plant and equipment	5	(4,988,613)	(1,710,032)
Payment to acquire intangible assets	7	-	(432,456)
Payments for Projects under construction		-	(9,763,220)
Proceeds from sale of property, plant and equipment		-	17,820
Interest received		24,455,517	3,743,857
Net cash flows generated from /(used in) investing activities		**19,466,904**	**(8,144,031)**
Cash flows from financing activities			
(Repayments of) Proceeds from facilities and related party loans		(227,115,443)	171,125,892
Repayments of facilities		(6,948,071)	(139,298,522)
Lease payments		(11,532,246)	(8,355,371)
Proceeds from Capital increase		570,206,456	-
Net cash flows generated from financing activities		**324,610,696**	**23,471,999**
Net increase in cash and cash equivalents		**304,079,633**	**47,232,328**
Cash and cash equivalents at the beginning of the period	11	**172,182,530**	**58,652,516**
Cash and cash equivalent at the end of the period		**476,262,163**	**105,884,844**

- The accompanying notes on pages 7 to 20 form an integral part of these interim condensed separate financial statements.

1. General information

Macro Group Pharmaceutical Company (Macro Capital) S.A.E. ("the Company") was established in Cairo - Egypt in 2005 as a general partnership Company according to the provision of law No. 8 of 1997. The Company was registered in the commercial register on 25 January 2005 under No. 6098.

In 2010 the articles of association were amended to reflect the change of the legal form of the Company to limited liability Company complying with the law No. 8 of 1997 and its executive regulations and to law No. 95 of 1992 and its executive regulations.

The Company's duration is 50 years started from the date of registration in the commercial register.

On 1 September 2020, the Company filed a request to the general authority for investment and free zone "GAFI" to approve the conversion of the Company's legal form from a Limited Liability Company (L.L.C.) to a Joint Stock Company (S.A.E.). "GAFI" approved on 18 January 2021 to change the legal form of the Company under the law no 72 for the year 2017.

The registered office of the Company is 83 Al Moltaqa Al Araby, Sheraton Cairo Egypt.

The Company is primarily involved in the production of all pharmaceutical products, cosmetic products, sanitizers, Flavours taste, colour and odour, production of all types and shapes of hard and liquid soap, Manufacturing and production of herbal medications, Herbal products and extracts, Nutritional supplements and baby nutrition.

The Company's immediate parent company is CHI Consumer Healthcare Investment (Mauritius), which is the controlling party, while the Company's ultimate parent company is Kingsway Fund (Luxembourg).

The Company received approval for its registration with the Financial Regulatory Authority (the "FRA"). The Shares were listed on the Egyptian Exchange (the "EGX") pursuant to the approval of the EGX listing committee convened on 12 January 2022, and trading in the Shares on the EGX commenced on 10 February 2022.

These interim condensed separate financial statements have been approved for issuance by the Board of Directors on 12 August 2026.

2. Basis of preparation of the interim condensed separate financial statements

2.1 Compliance with EAS

The interim condensed separate financial statements for the financial period ended 30 June 2026 have been prepared in accordance with the requirements of the Egyptian Accounting Standard (30) "Interim Financial Statements".

These interim condensed separate financial statements don't contain all the information required in preparing the full annual separate financial statements and should be read in conjunction with the Company's annual separate financial statements as at 31 December 2025.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

2. Basis of preparation of the interim condensed separate financial statements (continued)

2.1 Compliance with EAS (continued)

The accounting policies adopted in the preparation of these interim condensed separate financial statements are consistent with those of the previous financial year and corresponding interim reporting period. In addition, results of the six months period ended 30 June 2026 are not necessarily indicative for the results that may be expected for the financial year ending 31 December 2026.

3. Critical accounting estimates and assumptions.

Information about significant areas of estimation uncertainty and critical judgement in applying accounting policies that have the most significant effect on the amounts recognized in the interim condensed separate financial statement is described in the annual separate financial statements published for the year ended 31 December 2025.

In preparing these interim condensed separate financial statements, the significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that were applied to the separate financial statements for the year ended 31 December 2025.

4. Maturities of financial liabilities

The table below summarizes the maturities of the Company's undiscounted financial liabilities at 30 June 2026 and 31 December 2025, based on contractual payment dates and current market interest rates.

	Less than 6 months	Between 6 months & 1 year	Over 1 year
30 June 2026			
Lease liabilities	12,231,769	9,377,664	53,302,399
Trade and notes payables	100,266,754	-	-
Creditors and other credit balances	210,890,696	-	-
Due to related parties	20,081,802	-	-
Total	**343,471,021**	**9,377,664**	**53,302,399**
31 December 2025			
Lease liabilities	9,265,693	12,843,806	47,860,544
Bank facilities	6,948,071	-	-
Trade and notes payables	107,550,064	-	-
Accrued expenses and other credit balances	134,751,133	-	-
Due to related parties	22,093,724	-	-
Loans from related parties	145,788,760	-	94,770,148
Total	**426,397,445**	**12,843,806**	**142,630,692**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

5. Property, plant and equipment

	Land	Buildings	Machinery &equipment	Tools	Furniture & fixtures	Computers	Vehicles	Total
At 31 December 2025								
Cost	3,517,148	26,506,615	50,316,755	2,984,404	17,228,165	7,573,919	7,491,939	**115,618,945**
Accumulated depreciation	-	(3,929,183)	(15,860,697)	(2,208,675)	(3,719,779)	(4,624,154)	(3,206,820)	**(33,549,308)**
Net book value	**3,517,148**	**22,577,432**	**34,456,058**	**775,729**	**13,508,386**	**2,949,765**	**4,285,119**	**82,069,637**
Financial period ended 30 June 2026								
Net book value at the beginning of the period	**3,517,148**	**22,577,432**	**34,456,058**	**775,729**	**13,508,386**	**2,949,765**	**4,285,119**	**82,069,637**
Additions	-	388,250	1,978,500	1,320,266	65,351	1,236,246		**4,988,613**
Depreciation expense	-	(254,615)	(1,842,851)	(275,329)	(691,903)	(617,875)	(595,794)	**(4,278,367)**
Disposal	-	-	-	(14,900)	-	-	-	**(14,900)**
Accumulated depreciation relating to disposals	-	-	-	7,082	-	-	-	**7,082**
Net book value at the end of the period	**3,517,148**	**22,711,067**	**34,591,707**	**1,812,848**	12,881,834	3,568,136	3,689,325	**82,772,065**
At 30 June 2026								
Cost	3,517,148	26,894,865	52,295,255	4,289,770	17,293,516	8,810,165	7,491,939	**120,592,658**
Accumulated depreciation	-	(4,183,798)	(17,703,548)	(2,476,922)	(4,411,682)	(5,242,029)	(3,802,614)	**(37,820,593)**
Net book value	**3,517,148**	**22,711,067**	**34,591,707**	**1,812,848**	**12,881,834**	**3,568,136**	**3,689,325**	**82,772,065**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

6. Right of use assets

At 31 December 2025	
Cost	72,283,482
Accumulated amortization	(32,242,823)
Net book value	**40,040,659**
Financial period ended 30 June 2026	
Net book value at the beginning of the period	**40,040,659**
Additions	10,318,675
Amortization expense	(7,836,594)
Lease termination	(354,236)
Net book value at the end of the period	**42,168,504**
At 30 June 2026	
Cost	82,247,921
Accumulated amortization	(40,079,417)
Net book value	**42,168,504**

Right of use assets represents properties rented by the company.

7. Intangible assets

At 31 December 2025	
Cost	3,165,928
Accumulated amortization	(1,958,680)
Net book value	**1,207,248**
Financial period ended 30 June 2026	
Net book value at the beginning of the period	1,207,248
Amortization expense	(198,204)
Net book value at the end of the period	**1,009,044**
At 30 June 2026	
Cost	3,165,928
Accumulated amortization	(2,156,884)
Net book value	**1,009,044**

Intangible assets represent of computer system and software used by the Company.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

8. Inventories

	30 June 2026	31 December 2025
Raw materials	83,969,157	54,292,159
Finished Goods	78,964,656	58,965,240
Packing materials	62,334,604	58,963,349
Work in progress	7,939,455	30,004
Spare Parts	77,109	-
Total	**233,284,981**	**172,250,752**
Provision for obsolete and slow- moving inventory	(63,586,251)	(63,586,251)
Balance	**169,698,730**	**108,664,501**

The movement of the provisions are as follows:

	30 June 2026	31 December 2025
Balance at 1 January	**63,586,251**	**64,161,483**
Provision formed during the year	-	23,453,046
Inventory write-off	-	(24,028,278)
Balance	**63,586,251**	**63,586,251**

9. Trade and notes receivables

	30 June 2026	31 December 2025
Trade receivables	141,184,518	84,322,280
Notes receivables	406,999,893	334,327,012
Total	**548,184,411**	**418,649,292**
Provision for impairment of trade receivables	(22,954,711)	(22,954,711)
Provision for impairment of notes receivables	(84,159,747)	(84,159,747)
Right of return	(57,440,369)	(41,101,815)
Balance	**383,629,584**	**270,433,019**

The movement of the provisions for impairment of trades and notes receivables was as follows:

	30 June 2026	31 December 2025
Balance as of 1 January	**107,114,458**	**84,536,752**
Formed during the period/ year	-	29,577,706
No longer required	-	(7,000,000)
Balance	**107,114,458**	**107,114,458**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

10. Related party transactions

The Company entered into several transactions with other entities that fall under the definition of related parties in accordance with the disclosure's requirements of the Egyptian Accounting Standard No. 15 "Related party disclosure". Related parties are represented the Company's board of directors, companies under common ownership and/or common control, key management and the main Shareholders.

The Company has current accounts with its related parties, which include all payments made on behalf of or through shareholders and other affiliates. The Company collects and pays these amounts regularly.

Outstanding balances from related parties are unsecured and repayable on demand. No interest is usually charged on these balances.

10.1 Due from related parties' balances are as follows:

	Nature of relation	30 June 2026	31 December 2025
Macro Tech Macro Pex Group L.L.C	Subsidiary	1,509,871	1,353,040
Genova Pharmaceuticals L.L.C	Subsidiary	2,424,761	2,153,875
Zimer Egypt International Pharmaceuticals L.L.C	Subsidiary	1,212,418	968,418
Impairment of due from related parties		(3,990,008)	(3,990,008)
		1,157,042	**485,325**

The movement of the impairment of due from related parties was as follows:

	30 June 2026	31 December 2025
Balance as of 1 January	**3,990,008**	**867,715**
Formed during the period/ year	-	3,122,293
Balance	**3,990,008**	**3,990,008**

10.2 Due to related parties' balances are as follows:

	Nature of relation	30 June 2026	31 December 2025
Dot printing L.L.C	Subsidiary	20,081,802	22,093,724
		20,081,802	**22,093,724**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

10. Related Party transactions (continued)

10.3 Transactions with related parties

Name of the Company	Nature of relation	Nature of transactions	Value of transaction 30 June 2026	Value of transaction 31 December 2025
Genova Pharmaceuticals L.L.C	Subsidiary	Payment on behalf of the Company	270,888	275,685
		Bank transfers	-	(1,800,350)
Macro Tech Macro Pex Group L.L.C	Subsidiary	Payment on behalf of the Company	156,830	109,911
Dot printing L.L.C	Subsidiary	Purchases	(13,810,342)	(28,335,365)
		Payments made to related parties	15,845,212	28,103,655
Zimer Egypt International Pharmaceuticals L.L.C	Subsidiary	Payment on behalf of the Company	244,000	434,529

10.4 Key management remunerations

Key management remunerations amounted to EGP 22,244,762 for the period ended 30 June 2026 (30 June 2025: EGP 6,713,442). These amounts represent short-term employee benefits.

11. Cash and cash equivalent

	30 June 2026	31 December 2025
Bank deposits	301,225,855	30,308,679
Bank current accounts in local currency	164,660,800	121,556,696
Cash on hand	6,594,751	2,861,260
Bank current accounts - in foreign currencies	3,780,757	17,455,895
	476,262,163	**172,182,530**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

12. Capital

The paid-up capital amounted to EGP 684,247,747, divided into 3,421,238,736 shares, with a nominal value of EGP 0.20 per share.

The following table illustrates the paid-up capital as at 30 June 2026.

Shareholder Name	Nationality	Number of Shares	Ownership %	Par Value per Share	Total Value
CHI Consumer Healthcare Investment Company	Mauritius	1,500,471,628	43.86%	0.2	300,094,326
Remco EGT Investment L.L.C.	United Arab Emirates	410,952,858	12.01%	0.2	82,190,572
Inversson International	Mauritius	361,732,092	10.57%	0.2	72,346,418
Helikon Long Short Equity Fund Master ICAV	Ireland	122,958,681	3.59%	0.2	24,591,736
Ahmed El Naieb	Egypt	37,612,200	1.10%	0.2	7,522,440
Free Float	–	987,511,277	28.87%	0.2	197,502,255
Total		**3,421,238,736**	**100%**		**684,247,747**

The following table illustrates the paid-up capital for the year ended 31 December 2025.

Shareholder Name	Nationality	Number of Shares	Ownership %	Par Value per Share	Total Value
CHI Consumer Healthcare Investment Company	Mauritius	242,554,326	42.54%	0.2	48,510,865
Remco EGT Investment L.L.C.	United Arab Emirates	68,492,143	12.01%	0.2	13,698,429
Inversson International	Mauritius	58,480,021	10.26%	0.2	11,696,004
Helikon Long Short Equity Fund Master ICAV	Ireland	24,564,619	4.31%	0.2	4,912,924
MAE Healthcare Partners Limited	Mauritius	2,141	0.00%	0.2	428
Ahmed El Naieb	Egypt	6,268,700	1.10%	0.2	1,253,740
Free Float	–	169,844,506	29.79%	0.2	33,968,901
Total		**570,206,456**	**100%**		**114,041,291**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

13. Loans from related parties

13.1 Long term portion

	30 June 2026	31 December 2025
Long-term loan CHI Consumer Healthcare Investments Ltd	-	86,029,546
	-	**86,029,546**

During the financial period ended 30 June 2026, the Company made an early full repayment of the loan prior to its contractual maturity date of 3 June 2027. Accordingly, there is no outstanding loan balance as at 30 June 2026

13.2 Short term portion

	30 June 2026	31 December 2025
Short term loan – Enverson International company	-	141,085,897
	-	141,085,897

14. Provisions

	30 June 2026	31 December 2025
Balance at 1 January	**52,180,565**	**48,188,185**
Provision formed during the period/ year	10,172,912	21,476,728
Provisions no longer required	-	(725,184)
Provisions used during the period/ year	(1,674,511)	(16,759,164)
Balance	**60,678,966**	**52,180,565**

Provisions are related to claims expected to be made by third parties in connection with the Company's operations. The information usually required by accounting standards have not been disclosed because the management believes that to do so would seriously prejudice the outcome of the negotiations with those parties. Management reviews these provisions every period and the amount provided was adjusted based on latest developments, discussions and agreements with those parties.

15. Employees' Benefits

On 2 March 2026, the Company's Extraordinary General Assembly approved the adoption of the "Employee, Management, and Executive Board Members Incentive and Motivation of Macro Group for Pharmaceutical Industries S.A.E. through a stock sale commitment."

It was approved by the Financial Regulatory Authority (FRA) on 1 April 2026, provided that the service period for the first tranche is calculated starting from 1 March 2025.

The estimated present value of employees benefits at 30 June 2026 amounts to EGP 14,261,595

Definition:
A commitment will be made to sell shares of up to 1% annually of the Company's total issued shares, with an overall maximum of 5% of the issued shares up to an overall maximum of 5% of the issued shares over the entire duration of the system. . These shares will be allocated to employees, managers, and executive board members of the company and its subsidiaries, who are selected by the Supervisory Committee. It should be noted that the same beneficiary can be selected multiple times throughout the system's duration within this percentage limit, and the Supervisory Committee may include additional beneficiaries during the system period.

Beneficiaries must be employees of the Company's management or its subsidiaries, executives, heads of sectors or departments, sector or department managers and their deputies. The beneficiary must have completed at least three months of service with the Company, have obtained a performance rating of "Very Good" or higher in the most recent evaluation prior to the allocation decision, and must maintain this performance level prior to each grant date.

Plan Duration: The employee Benefits is divided into a maximum of five (5) annual tranches, whereby each beneficiary is allocated a specific number of units in accordance with the decision of the Supervisory Committee.

Promise to Sell Agreement: Upon expiration of the promise period stated in the promise-to-sell contract, the beneficiary has the right to exercise their option during the exercise period, and settlement is carried out using one of the following two methods:

The undertaking period for the first tranche is one month from the date of FRA approval of the scheme or 1 March 2026, whichever is later. The undertaking period for each subsequent tranche is one year from the date of the share sale undertaking agreement. The exercise period is determined as 30 days from the end of the undertaking period.

Upon the expiry of the undertaking period stipulated in the share sale undertaking agreement, the beneficiary is entitled to exercise his/her right during the exercise period, and settlement shall be made using one of the following methods:

Equity-settled: The beneficiary pays 5% of the par value of each allocated share in exchange for the transfer of ownership of the shares to him/her; or Cash-settled: At the Company's discretion, the Company grants the beneficiary a cash consideration equivalent to the value of the allocated shares instead of transferring ownership of the shares. In this case, the beneficiary shall not have the right to request the transfer of ownership of any shares.

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

15. Employees' Benefits (continued)

(1) Forfeiture of Rights: In the event that the beneficiary fails to exercise their right within the designated Exercise Period, their right to the respective shares shall be forfeited.

(2) The shares allocated to the beneficiary are calculated according to the following formula:

The difference between (1) the weighted average share price (weighted average price) determined in the month prior to the allocation date and (2) the weighted average share price (weighted average price) determined in the month preceding the commencement date of exercising the right, which is the expiration date of one year since the date of each allocation (the "share price when exercising the right"). The result is then multiplied by the number of units allocated to each segment assigned to each beneficiary, and the aforementioned output is divided by the share price when exercising the right, resulting in the final number of shares allocated to the beneficiary ("the final number of shares"), with the aim of linking the economic interest of the beneficiaries of the plan with the interests of the Company's shareholders

16. Bank facilities

	30 June 2026	31 December 2025
Bank facilities	-	6,948,071
	-	**6,948,071**

Movement of bank facilities during the six months period ended 30 June 2026 and 30 June 2025 was as follows:

	30 June 2026	30 June 2025
Balance at 1 January	**6,948,071**	**74,834,792**
Proceeds from facilities	-	85,389,826
Repayments of facilities	(6,948,071)	(139,298,522)
Balance	**-**	**20,926,096**

17. Creditors and other credit balances

	30 June 2026	31 December 2025
Accrued Expenses	105,269,874	67,968,373
Refund Liabilities	45,925,074	43,677,793
Tax Authority	28,763,754	18,922,157
Accrued Dividends	26,431,645	431,647
Advances from Customers	4,400,334	3,666,163
Other Credit Balances	100,015	85,000
Balance	**210,890,696**	**134,751,133**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

18. Sales (net)

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Local sales	561,079,853	393,880,518	293,618,086	215,105,050
Export sales	14,125,253	17,516,000	9,329,467	11,978,294
	575,205,106	**411,396,518**	**302,947,553**	**227,083,344**

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Gross sales	625,163,274	452,893,496	337,075,754	247,204,807
Less: right of return	(18,585,834)	(22,394,976)	(10,004,386)	(11,820,461)
Less: discounts	(31,372,334)	(19,102,002)	(24,123,815)	(8,301,002)
Net sales	**575,205,106**	**411,396,518**	**302,947,553**	**227,083,344**

*The Company recognizes revenue at a point in time.

19. Expenses by nature

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Cost of sales	169,265,573	131,268,830	88,489,455	69,136,184
Selling and marketing expenses	192,488,094	130,959,489	102,600,653	73,502,594
General and administrative expenses	99,838,601	57,479,833	43,815,324	28,017,620
	461,592,268	**319,708,152**	**234,905,432**	**170,656,398**
Staff costs	199,801,618	127,549,646	91,812,843	66,298,927
Raw material cost	134,128,079	100,990,189	71,284,171	54,215,701
Marketing and advertising expenses	67,930,937	32,655,673	39,714,014	20,808,492
Meetings and accommodation expenses	10,699,399	11,188,058	7,538,046	6,589,780
Professional fees	8,734,018	8,248,487	4,994,924	2,781,284
Right of use amortization (Note 6)	7,836,594	5,842,549	4,025,296	2,972,105
License and subscription fees	6,546,347	6,582,788	3,061,366	2,309,677
Depreciation expense (Note 5)	4,278,367	2,214,622	2,182,846	1,111,284
Goods distribution expense	4,454,440	3,439,666	2,431,949	2,047,130
Transportation and travel expenses	2,923,053	3,145,028	1,312,577	1,784,124
Repair and maintenance	2,546,154	2,371,531	1,268,697	1,035,716
Utilities expense	1,854,146	1,355,327	723,259	716,408
Health insurance	1,551,610	1,039,636	839,453	572,137
Storage Expenses	1,488,000	810,079	836,416	510,128
Security	1,341,701	1,043,222	617,101	498,235
Supplies	1,008,195	1,890,671	469,457	1,203,769
1% training fund	24,477	715,145	24,477	715,145
Intangible assets amortization (Note 7)	198,204	180,185	99,102	108,122
Provision for obsolete inventory	-	5,988,173	-	2,956,386
Other expenses	4,246,929	2,457,477	1,669,438	1,421,848
	461,592,268	**319,708,152**	**234,905,432**	**170,656,398**

(In the notes all amounts are shown in Egyptian Pounds unless otherwise stated)

20. Finance cost - Net

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Foreign exchange gain	-	4,197,325	-	3,157,238
Interest income	24,455,517	3,743,857	12,591,025	2,290,449
Finance income	**24,455,517**	**7,941,182**	**12,591,025**	**5,447,687**
Interest expense	(997,149)	(16,248,888)	(902,266)	(7,645,702)
Foreign exchange loss	(12,572,668)	-	(4,326,916)	-
Lease interest expense	(5,274,291)	(3,139,311)	(2,701,918)	(1,393,408)
Finance cost	**(18,844,108)**	**(19,388,199)**	**(7,931,100)**	**(9,039,110)**
Net finance income/(cost)	**5,611,409**	**(11,447,017)**	**4,659,925**	**(3,591,423)**

21. Earnings per share

Basic share earnings for the period is calculated by dividing the net profit for the period attributable to the shareholders of the parent company by the weighted average number of shares outstanding during the period, excluding ordinary shares purchased during the period.

	For the six months ended 30 June		For the three months ended 30 June	
	2026	**2025**	**2026**	**2025**
Net profit for the period	85,811,683	71,283,081	52,194,416	46,825,936
Weighted average number of ordinary issued and paid shares	2,554,902,960	570,206,456	3,421,238,736	570,206,456
Basic earnings per share	**0.03**	**0.13**	**0.02**	**0.08**

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. The Company does not have any categories of dilutive potential ordinary shares on 30 June 2026 and 30 June 2025 hence the diluted earnings per share is the same as the basic earnings per share.

22. Segment reporting

The Company's activities are organized into one segment which is related to the manufacturing and sale of cosmetics. This is in accordance with the presentations to the Board of Directors. Therefore, entity wide information required under EAS 41 "operating segments" are already included in the interim condensed separate financial statements, so no further information require disclosures.

23. Contingent liabilities

The Company has no contingent liabilities in respect of letters of credit arising from ordinary course of business as of 30 June 2026 and 31 December 2025.

24. Capital Commitments

The Company has no capital commitments contracted at the date of the financial statements that have not yet been received.

25. Significant Events

Regional Geopolitical Developments

Security tensions and developments in the Middle East region have escalated, contributing to increased instability and geopolitical and economic uncertainty in the region.

Management believes that the duration of these developments and their potential impact remain uncertain and cannot be reliably estimated as at the date of authorization for issue of these financial statements. Accordingly, no adjustments have been made to these financial statements.